Published in Ann Rheum Dis on December 01, 2002
Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis (2004) 2.26
European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut (2006) 1.87
Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest (2005) 1.73
Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care. Ann Rheum Dis (2004) 1.49
Performance of referral recommendations in patients with chronic back pain and suspected axial spondyloarthritis. Ann Rheum Dis (2007) 1.34
Ankylosing spondylitis: recent breakthroughs in diagnosis and treatment. J Can Chiropr Assoc (2007) 1.34
The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Ann Rheum Dis (2007) 1.14
How early should ankylosing spondylitis be treated with tumour necrosis factor blockers? Ann Rheum Dis (2005) 1.09
An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis. Ann Rheum Dis (2006) 1.02
A systematic MEDLINE analysis of therapeutic approaches in ankylosing spondylitis. Rheumatol Int (2009) 0.98
Cancer incidence among patients with ankylosing spondylitis in Sweden 1965-95: a population based cohort study. Ann Rheum Dis (2003) 0.97
Disease activity in longstanding ankylosing spondylitis: a correlation of clinical and magnetic resonance imaging findings. Clin Rheumatol (2007) 0.90
Exercise and inflammatory bowel disease. Can J Gastroenterol (2008) 0.87
Effects of physical therapy for the management of patients with ankylosing spondylitis in the biological era. Clin Rheumatol (2014) 0.84
Treat ankylosing spondylitis with methazolamide. Int J Med Sci (2011) 0.83
Efficacy and safety of celecoxib in chinese patients with ankylosing spondylitis: a 6-week randomized, double-blinded study with 6-week open-label extension treatment. Curr Ther Res Clin Exp (2014) 0.82
The rate and significance of Mediterranean fever gene mutations in patients with ankylosing spondylitis: a three-month, longitudinal clinical study. Rheumatol Int (2008) 0.80
Increased expression of glucocorticoid receptor beta messenger RNA in patients with ankylosing spondylitis. Korean J Intern Med (2005) 0.80
Health-related Quality of Life Assessment on 100 Tunisian Patients with Ankylosing Spondylitis using the SF-36 Survey. Oman Med J (2012) 0.78
The high prevalence of infections and allergic symptoms in patients with ankylosing spondylitis is associated with clinical symptoms. Clin Rheumatol (2005) 0.78
Celecoxib and sulfasalazine had negative association with coronary artery diseases in patients with ankylosing spondylitis: A nation-wide, population-based case-control study. Medicine (Baltimore) (2016) 0.77
Effect of Pilates training on people with ankylosing spondylitis. Rheumatol Int (2011) 0.77
Impact on total population health and societal cost, and the implication on the actual cost-effectiveness of including tumour necrosis factor-α antagonists in management of ankylosing spondylitis: a dynamic population modelling study. Cost Eff Resour Alloc (2015) 0.77
Management of arthropathy in inflammatory bowel diseases. Ther Adv Chronic Dis (2015) 0.77
Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab. BMC Musculoskelet Disord (2015) 0.77
[Ankylosing spondylitis in Central and Eastern Europe. Cross-sectional study on treatment modalities, disease activity and quality of life]. Z Rheumatol (2008) 0.76
Evaluation of the short-term efficacy of NSAIDs on patients with active ankylosing spondylitis in daily practice: a 3-month, longitudinal, observational study. Rheumatol Int (2009) 0.76
Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study. Arthritis Res Ther (2014) 0.76
Infliximab in the treatment of ankylosing spondylitis. Biologics (2007) 0.76
Efficacy of SLZ and MTX (alone or combination) on the treatment of active sacroiliitis in early AS. Rheumatol Int (2009) 0.75
Treatment of Extraintestinal Manifestations in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol (2003) 0.75
Efficacy of an acquainted drug in the treatment of inflammatory low back pain: sulfasalazine under investigation. Drug Des Devel Ther (2016) 0.75
Clinical observations programme in SpA: disease parameters, treatment options and practical management issues. Rheumatol Int (2008) 0.75
[Biologics in the early treatment of ankylosing spondylitis and related forms of spondyloarthritis]. Wien Med Wochenschr (2008) 0.75
Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA (2001) 13.93
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet (1996) 13.20
Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (1995) 9.77
Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum (2001) 4.57
Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA (1999) 4.25
Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA (1999) 3.60
[Criteria of the classification of spondylarthropathies]. Rev Rhum Mal Osteoartic (1990) 3.04
Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther (1989) 2.51
Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum (1995) 2.16
Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis. J Rheumatol (1999) 2.12
Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol (1997) 2.11
A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum (2002) 1.97
Combined spa-exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum (2001) 1.86
Total hip arthroplasty in ankylosing spondylitis: outcome in 340 patients. J Rheumatol (2001) 1.71
Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum (2001) 1.68
Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum (1999) 1.65
Incidence of sulphasalazine-induced male infertility. Gut (1981) 1.58
Lumbar osteotomy for correction of thoracolumbar kyphotic deformity in ankylosing spondylitis. A structured review of three methods of treatment. Ann Rheum Dis (1999) 1.53
From experiment to experience: side effects of nonsteroidal anti-inflammatory drugs. Am J Med (1983) 1.50
Neurological complications of ankylosing spondylitis. J Neurosurg (1993) 1.43
Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum (1996) 1.35
Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int (1999) 1.31
Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis: clinical outcome and followup by dynamic magnetic resonance imaging. J Rheumatol (1996) 1.30
Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology (Oxford) (1999) 1.28
Assessment of the efficacy of sacroiliac corticosteroid injections in spondylarthropathies: a double-blind study. Br J Rheumatol (1996) 1.27
Double-blind cross-over comparison of indomethacin, flurbiprofen, and placebo in ankylosing spondylitis. Ann Rheum Dis (1974) 1.23
Adverse effects of bisphosphonates. A comparative review. Drug Saf (1996) 1.12
Management of rheumatoid arthritis: the historical context. J Rheumatol (2001) 1.09
[Evaluation of the Amor criteria for spondylarthropathies and European Spondylarthropathy Study Group (ESSG). A cross-sectional analysis of 2,228 patients]. Ann Med Interne (Paris) (1991) 1.09
The effects of comprehensive home physiotherapy and supervision on patients with ankylosing spondylitis--a randomized controlled trial. J Rheumatol (1990) 1.05
Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy. J Rheumatol (2001) 1.05
Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res (1995) 1.00
Clinical and biochemical response to single infusion of pamidronate in patients with active rheumatoid arthritis: a double blind placebo controlled study. J Rheumatol (1994) 1.00
What do we know about the sacroiliac joint? Semin Arthritis Rheum (1983) 1.00
Double-bind cross-over tiral of flurbiprofen and phenylbutazone in ankylosing spondylitis. Br Med J (1974) 0.99
Comparative antiinflammatory and bone protective effects of two diphosphonates in adjuvant arthritis. Arthritis Rheum (1979) 0.99
Meta-analysis of sulfasalazine in ankylosing spondylitis. J Rheumatol (1990) 0.97
Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study. Clin Rheumatol (2000) 0.97
An open study of pamidronate in the treatment of refractory ankylosing spondylitis. J Rheumatol (1998) 0.97
Clinical, biochemical, and radiographic effects of aminohydroxypropylidene bisphosphonate treatment in rheumatoid arthritis. Ann Rheum Dis (1989) 0.96
A study to determine the active moiety of sulphasalazine in rheumatoid arthritis. J Rheumatol (1986) 0.93
NE-58095: a diphosphonate which prevents bone erosion and preserves joint architecture in experimental arthritis. Int J Tissue React (1989) 0.91
Two year followup of anterior and vertical atlantoaxial subluxation in ankylosing spondylitis. J Rheumatol (1997) 0.91
COX-1-sparing NSAIDs--is the enthusiasm justified? JAMA (1999) 0.89
Demonstration of novel anti-arthritic and anti-inflammatory effects of diphosphonates. J Pharmacol Exp Ther (1993) 0.89
Spondylarthropathy treatment: progress in medical treatment, physical therapy and rehabilitation. Baillieres Clin Rheumatol (1998) 0.87
Bisphosphonates and breast carcinoma: present and future. Cancer (2000) 0.86
Ximoprofen in ankylosing spondylitis. A double blind placebo controlled dose ranging study. Scand J Rheumatol (1994) 0.86
Intravenous methylprednisolone pulse therapy in ankylosing spondylitis. Scand J Rheumatol (1992) 0.86
Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease. Drug Saf (1991) 0.86
Continuation of group physical therapy is necessary in ankylosing spondylitis: results of a randomized controlled trial. Arthritis Care Res (1994) 0.84
Magnetic resonance imaging guided corticosteroid injection of the sacroiliac joints in patients with therapy resistant spondyloarthropathy: a pilot study. J Rheumatol (2000) 0.83
Treatment of spondyloarthropathies. Recent advances and prospects in 2001. Joint Bone Spine (2001) 0.82
A double blind crossover placebo controlled trial of ximoprofen in as. J Rheumatol (1989) 0.82
Which is the active moiety of sulfasalazine in ankylosing spondylitis? A randomized, controlled study. Arthritis Rheum (1996) 0.81
Side effects of sulphasalazine in patients with rheumatic diseases or inflammatory bowel disease. Scand J Rheumatol (1994) 0.80
Oral quinine in ankylosing spondylitis: a randomized placebo controlled double blind crossover trial. J Rheumatol (2000) 0.80
Ankylosing spondylitis successfully treated with methotrexate. Intern Med (1993) 0.79
The effects of intravenous pulse methylprednisolone on immunological and inflammatory processes in ankylosing spondylitis. Clin Exp Immunol (1983) 0.79
Dramatic response after an intravenous loading dose of azathioprine in one case of severe and refractory ankylosing spondylitis. Rheumatology (Oxford) (2000) 0.78
Clinical efficacy of mesalamine in the treatment of the spondyloarthropathies. J Rheumatol (2000) 0.78
Treatment of spondyloarthropathy with 5-aminosalicylic acid (mesalazine): an open trial. J Rheumatol (2000) 0.77
Management of complications of glucocorticoid therapy. Clin Chest Med (1997) 0.77
[Indications and contraindications for systemic gold therapy]. Wien Klin Wochenschr Suppl (1984) 0.76
The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum (1991) 11.66
Full-genome RNAi profiling of early embryogenesis in Caenorhabditis elegans. Nature (2005) 9.50
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis (2009) 8.37
Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet (2002) 6.12
The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis (2010) 5.24
Production of enterotoxin a. Appl Microbiol (1966) 4.99
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2011) 4.78
Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell (1999) 4.38
The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis (2009) 4.37
ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2005) 4.31
Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2006) 4.27
Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls. Lancet (1996) 4.20
The natural history of recovery for the healthcare provider "second victim" after adverse patient events. Qual Saf Health Care (2009) 3.79
Informed choice in genetic screening for thalassaemia during pregnancy: audit from a national confidential inquiry. BMJ (2000) 3.38
Long-term pacing in sinus node disease: effects of stimulation mode on cardiovascular morbidity and mortality. Am Heart J (1988) 3.33
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis (2009) 3.32
A distinct picornavirus group identified by sequence analysis. Proc Natl Acad Sci U S A (1992) 3.28
Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA (1997) 3.17
Effects of thermoperiod on recovery of seed germination of halophytes from saline conditions. Am J Bot (1997) 3.02
Effect of brain edema on infarct volume in a focal cerebral ischemia model in rats. Stroke (1993) 2.85
International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis (2003) 2.85
Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology (2004) 2.81
Motor disorder in Huntington's disease begins as a dysfunction in error feedback control. Nature (2000) 2.81
Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum (2003) 2.78
Gigantomastia--a classification and review of the literature. J Plast Reconstr Aesthet Surg (2007) 2.72
Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet (2000) 2.66
Construct and concurrent validity of the Hopkins Verbal Learning Test-revised. Clin Neuropsychol (1999) 2.65
A Bayesian approach for estimating values for prevalence and diagnostic test characteristics of porcine cysticercosis. Int J Parasitol (2004) 2.34
Molecular and biological characteristics of echovirus 22, a representative of a new picornavirus group. J Virol (1994) 2.27
Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis (2004) 2.26
New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis (2009) 2.22
Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum (2003) 2.20
Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum (1995) 2.16
A multidisciplinary approach for improving services in primary care: randomised controlled trial of screening for haemoglobin disorders. BMJ (1998) 2.14
Caenorhabditis elegans expressed sequence tags identify gene families and potential disease gene homologues. Nat Genet (1992) 2.10
Atrial versus ventricular pacing in sinus node disease: a treatment comparison study. Am Heart J (1986) 2.05
Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis (2002) 2.02
Enkephalin-like immunoreactivity in gland cells and nerve terminals of the adrenal medulla. Neuroscience (1978) 2.01
Time-dependent motor memory processes in amnesic subjects. J Neurophysiol (1998) 1.99
Association between executive attention and physical functional performance in community-dwelling older women. J Gerontol B Psychol Sci Soc Sci (1999) 1.98
Psychological costs and benefits of predictive testing for Huntington's disease. Am J Med Genet (1994) 1.94
Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology (1995) 1.92
APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease. Neurology (2008) 1.91
Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis (2003) 1.91
Distinct short-lived and long-lived antibody-producing cell populations. Eur J Immunol (1986) 1.89
Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis (2006) 1.86
Self-selection in predictive testing for Huntington's disease. Am J Med Genet (1994) 1.84
A national register for surveillance of inherited disorders: beta thalassaemia in the United Kingdom. Bull World Health Organ (2001) 1.83
Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) (2005) 1.82
Quality of life in patients with Alzheimer's disease as reported by patient proxies. J Am Geriatr Soc (1996) 1.78
Epidemiology of eltor cholera in rural Bangladesh: importance of surface water in transmission. Bull World Health Organ (1982) 1.75
Exploring the scope for advocacy by paediatricians. Arch Dis Child (1999) 1.74
Dementia in hippocampal sclerosis resembles frontotemporal dementia more than Alzheimer disease. Neurology (2004) 1.74
Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. Arch Neurol (1996) 1.74
Apolipoprotein E genotype and rate of decline in probable Alzheimer's disease. Arch Neurol (1996) 1.74
Covalent attachment of proteins to polysaccharide carriers by means of benzoquinone. Biochim Biophys Acta (1975) 1.73
Migrant mu+ delta+ and static mu+ delta- B lymphocyte subsets. Eur J Immunol (1982) 1.71
The General Medical Health Rating: a bedside global rating of medical comorbidity in patients with dementia. J Am Geriatr Soc (1999) 1.71
Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease. Mov Disord (2000) 1.67
Longitudinal study of effects of patient characteristics on direct costs in Alzheimer disease. Neurology (2006) 1.65
Comparative full genome analysis revealed E1: A226V shift in 2007 Indian Chikungunya virus isolates. Virus Res (2008) 1.64
Quality of life in dementia patients in long-term care. Int J Geriatr Psychiatry (2000) 1.64
The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry (1997) 1.63
Epicardial right atrial free wall mapping in chronic atrial fibrillation. Documentation of repetitive activation with a focal spread--a hitherto unrecognised phenomenon in man. Eur Heart J (1997) 1.63
Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons. Neurology (1994) 1.61
A subset of CD4+ memory T cells contains preformed CD40 ligand that is rapidly but transiently expressed on their surface after activation through the T cell receptor complex. J Exp Med (1995) 1.60
Motor signs predict poor outcomes in Alzheimer disease. Neurology (2005) 1.60
Age at onset of Alzheimer's disease: relation to pattern of cognitive dysfunction and rate of decline. Neurology (1994) 1.60
Gender affects sympathetic and hemodynamic response to postural stress. Am J Physiol Heart Circ Physiol (2001) 1.60
Infliximab treatment of severe ankylosing spondylitis: one-year followup. Arthritis Rheum (2001) 1.58
Wound botulism in drug addicts in the United Kingdom. Anaesthesia (2001) 1.57
Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease. Brain (1999) 1.56
Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems. Ann Rheum Dis (2004) 1.56
Botulinum toxin for the treatment of lower urinary tract symptoms: a review. Neurourol Urodyn (2005) 1.53
Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis (2004) 1.53
The effectiveness of patient referral in Pakistan. Health Policy Plan (2001) 1.51
Assessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging: a comparison between contrast enhanced T1 and short tau inversion recovery (STIR) sequences. Ann Rheum Dis (2005) 1.51
Pulmonary haemorrhage in low-birthweight babies. Lancet (1993) 1.50
Intelligence and education as predictors of cognitive state in late life: a 50-year follow-up. Neurology (1995) 1.50
Contribution of systematic serological testing in diagnosis of infective endocarditis. J Clin Microbiol (2005) 1.50
Cerebral infarct following central venous cannulation. Anaesthesia (1998) 1.50
Pyrogenicity of poly I. poly C in rabbits. Nature (1969) 1.49
Motor signs during the course of Alzheimer disease. Neurology (2004) 1.47
Radiographic assessment of sacroiliitis by radiologists and rheumatologists: does training improve quality? Ann Rheum Dis (2003) 1.46
Cloning and sequencing of the immunoglobulin A1 protease gene (iga) of Haemophilus influenzae serotype b. Infect Immun (1989) 1.45
Dendritic cells associated with plasmablast survival. Eur J Immunol (1999) 1.44
Biliary ascariasis. Indian J Gastroenterol (1989) 1.43
Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis (2007) 1.43
Inflammatory role and prognostic value of platelet chemokines in acute coronary syndrome. Thromb Haemost (2014) 1.42
Improved cardiac function and quality of life following upgrade to dual chamber pacing after long-term ventricular stimulation. Eur Heart J (2002) 1.42
Seroepidemiologic studies during a simultaneous epidemic of infection with El Tor Ogawa and classical Inaba Vibrio cholerae. J Infect Dis (1970) 1.40
Recording diastolic blood pressure in pregnancy. BMJ (1990) 1.40
Arthroscopic repair of full-thickness tears of the rotator cuff. J Bone Joint Surg Am (1998) 1.40
Universal pattern of RpoB gene mutations among multidrug-resistant isolates of Mycobacterium tuberculosis complex from Africa. Int J Tuberc Lung Dis (1999) 1.39
HLA-B27 and arthritis: back to the future. Part I. J Rheumatol (1991) 1.39